Overview

Prevention Study in Adult Patients Suffering From Migraine Headaches

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk flexible titration period and then enter the 12 week maintenance period.
Phase:
Phase 2
Details
Lead Sponsor:
XenoPort, Inc.
Collaborator:
GlaxoSmithKline